Patent infringement damages
Patent infringement damages only much more interesting. It turns out that if we could optimize the operation of your intellectual property rights, to lose one. A recent decision in Arizona District Court of Bard Peripheral Vascular, Inc. v. WL Gore Inc. (No. CV-03-0597-PHX-MHM) Bard denied a permanent injunction, because a better product with Gore's patented technology that Bard Bard.
Bard argues that Gore sells two types of counterfeit goods. The first group are products sold for Bard, an alternative, almost identical counterpart. These products are called "Counterpart of products".
These include PROP ATHENS transplants Not Call transplants, cardiovascular patches, and other variants of these grafts and patches. The second group of products is a service of the Bard does not currently offer an alternative to insist on the market. These are called "non-equivalent products. 'These include VIABAHN Gore stent-graft, Excluder stent-graft, TAG stent-graft, VIATORR stent-graft, ACUSEAL spots, and other products.
Bard argues that permanent Gore drew on the production and sale of Counterpart of products, non-equivalent products, and hurt each new development, including products for which there is or is currently seeking FDA approval.
The court heard testimony from surgeons to tell the superiority of the implementation of Gore's Bard's patented technology. As a result, the Court decided not to command Gore.
Bard had lost profits for the revaluation made and produced and sold is from Gore and received a royalty on sales of non-Counterpart Products. What is now clearly over, as Gore Bard for the future use of the Bard's remuneration is no longer the exclusive patent rights.
The parties are likely to reach an agreement on the future royalties Bard Gore will pay compensation for non-income products. The difficult question is how to compensate for future sales Gore Bard of Counterpart of products, when the Bard is in direct competition with each other. Bard lose future sales and future incremental results.
A typical royalty rate is not enough to be lost for future Bard compensate for the extra benefits. Currently, a plaintiff can win a patent case, but loses the exclusive right to use their own patented technologies.
